Rights and permissions
About this article
Cite this article
Ibritumomab tiuxetan Y-90 receives priority review.. Inpharma Wkly. 1667, 22 (2008). https://doi.org/10.2165/00128413-200816670-00077
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200816670-00077